Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02681094

Public ClinicalTrials.gov record NCT02681094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.

Study identification

NCT ID
NCT02681094
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
905 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 25, 2016
Primary completion
Jul 14, 2017
Completion
Jul 14, 2017
Last update posted
Oct 9, 2018

2016 – 2017

United States locations

U.S. sites
48
U.S. states
19
U.S. cities
44
Facility City State ZIP Site status
Research Site Saraland Alabama 36571
Research Site Fresno California 93702
Research Site Harbor City California 90710
Research Site Hawaiian Gardens California 90716
Research Site Lancaster California 93534
Research Site Los Angeles California 90057
Research Site Montclair California 91763
Research Site Pomona California 91767
Research Site Spring Valley California 91978
Research Site Vallejo California 94592
Research Site Denver Colorado 80220
Research Site Northglenn Colorado 80234
Research Site Wheat Ridge Colorado 80033
Research Site Waterbury Connecticut 06708
Research Site Cooper City Florida 33024
Research Site Doral Florida 33166
Research Site Hialeah Florida 33012
Research Site Miami Florida 33176
Research Site Miami Florida 33186
Research Site Miami Lakes Florida 33016
Research Site Buford Georgia 30518
Research Site Chicago Illinois 60607
Research Site Hazel Crest Illinois 60429
Research Site New Orleans Louisiana 70115
Research Site Zachary Louisiana 70791
Research Site Biloxi Mississippi 39531
Research Site Florissant Missouri 63031
Research Site Albany New York 12203
Research Site The Bronx New York 10459
Research Site Asheville North Carolina 28801
Research Site Mooresville North Carolina 28117
Research Site Fargo North Dakota 58103
Research Site Columbus Ohio 43201
Research Site Maumee Ohio 43537
Research Site East Providence Rhode Island 02914
Research Site West Columbia South Carolina 29169
Research Site Dallas Texas 75208
Research Site Dallas Texas 75230
Research Site El Paso Texas 79935
Research Site Fort Worth Texas 76132
Research Site Houston Texas 77004
Research Site Houston Texas 77036
Research Site Houston Texas 77040
Research Site Odessa Texas 79761
Research Site Sugar Land Texas 77479
Research Site Waco Texas 76710
Research Site Salt Lake City Utah 84102
Research Site Norfolk Virginia 23510

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02681094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02681094 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →